Cargando...
Combining immunotherapies for the treatment of prostate cancer
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate can...
Guardado en:
| Publicado en: | Urol Oncol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6599516/ https://ncbi.nlm.nih.gov/pubmed/29146441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.09.024 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|